Several factors contribute to the translational gap in cancer research. One major factor is the complexity of cancer itself. Cancer is not a single disease but a collection of related diseases, each with its own unique genetic and molecular characteristics. This diversity makes it difficult to develop universal treatments. Another factor is the lengthy and costly process of drug development. It often takes years of research and millions of dollars to bring a new treatment from the lab to the clinic. During this process, potential treatments must undergo rigorous testing in preclinical studies and clinical trials to ensure their safety and efficacy.
